Polypharmacy in patients with chronic-degenerative diseases in a remote community, Puebla- México.


Autores/as

  • Veronica Sánchez-Hernádez Centro de Estudios Superiores de Tepeaca
  • Marlen Morales-Pérez, M Sc Oncology Center of the Social Security Institute of the State of Mexico and Municipalities, Toluca, México
  • Angélica Osorio-Espinoza Centro de Estudios Superiores de Tepeaca http://orcid.org/0000-0001-8081-2321

DOI:

https://doi.org/10.22517/25395203.25046

Palabras clave:

diabetes mellitus type 2, polypharmacy, chronic diseases, dyslipidemia, Systemic Arterial Hypertension

Resumen

Objective: To determine if patients with chronic degenerative diseases between 50-90 years of age have polypharmacy and drug interactions, at the Huajoyuca Health Center of Palacios, between June 2018-June 2019.

Methodology: A descriptive, observational, non-experimental, statistical, retrospective, cross-sectional, unicentric research was carried out. The sample consisted of 56 files according to the inclusion criteria. Data were analyzed according to descriptive statistics and frequency histograms.

Results: The mean age is 67.11 ± 9.6 years. There was a higher prevalence of polypharmacy in the 60-69 age range. Due to excessive medication consumption, women make up 82 percent of those affected. Patients with chronic-degenerative disorders are the most likely to have polypharmacy, and those with comorbid conditions even more, it was observed that the consumption and frequency of medications per patient is 4.08 ± 1.56 medications. The top drugs consumed daily are metformin (17.41%), hydrochlorothiazide (12.05%), B vitamin, acetylsalicylic acid glibenclamide with (11.16%), losartan (8.03%), enalapril (6.69%), captopril (4.91 %). 38 patients with (68%) had minor polypharmacy, 17 patients with (30%) had major polypharmacy, and 1 patient with (2%), had excess polypharmacy.

Conclusion: In order from highest to lowest, patients with type 2 diabetes mellitus have minor polypharmacy, unlike hypertensive and dyslipidemic patients. The gender most affected by polypharmacy is the female with 82% vs. 18% the male gender of the population studied.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Veronica Sánchez-Hernádez, Centro de Estudios Superiores de Tepeaca

Estudiante de Licenciatura en Médico Cirujano y Partero

 

Marlen Morales-Pérez, M Sc, Oncology Center of the Social Security Institute of the State of Mexico and Municipalities, Toluca, México

Licenciada en Farmacia.

Magíster en Oncología Farmacéutica.

 

Citas

Tagle R. Diagnosis of arterial hypertension. Rev. Med. Clin Condes. 2018; 29 (1) 12-20.

López Ruz J.C., Letamendi Velaso J.A., Calderon León R.A. Prevalencia de dislipidemias en pacientes obesos. Medisan [Internet]. 2020 Abr [citado 2022 Jul 11] ; 24( 2 ): 211-222. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192020000200211&lng=es.

Rivas-Alpizar E, Zerquera-Trujillo G, Hernández-Gutiérrez C, Vicente-Sánchez B. Manejo práctico del paciente con diabetes mellitus en la Atención Primaria de Salud. Revista Finlay [Internet]. 2011 [citado 2022 Jul 11]; 1(3):[aprox. 22 p.]. Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/69

Ramírez JAC, Orozco Hernández JPP, Marín Medina DS. Polifarmacia y prescripción de medicamentos potencialmente no apropiados en ancianos. Rev. Médica Risaralda [Internet] 31 de diciembre de 2015 [citado 11 de julio de 2022];21(2). Disponible en: https://revistas.utp.edu.co/index.php/revistamedica/article/view/12451

Girona L, Juárez C, Lalueza P. Drug interactions: a professional challenge. Farm Hosp. 2014; 38 (3): 151-153.

Robles AR, Hernández EK, Delabra MM, Covarrubias IF, Leija A, and Ponce BB. Quality of Life (QOL) and polypharmacy in the Older Adults Program “packers”, Nure Inv, 2017, 14 (91) 1-9.

Urra M, Germán JL. Polypharmacy in the elderly. Habanera Magazine of Medical Sciences, 2013: 12 (1) 142-151.

García Chairez AL, Pinedo SR, Zegbe JA, de Chávez D. Polypharmacy in the Elderly at First Level of Care. Iban Sina, 2017,2; 1-15.

Cala L, Casas S, Kadel L. Cascade effect in the ederly as a consequence of polypharmacy, Medisan 2017; 31 (3): 279-286.

Scottish Government. Polypharmacy Model of Care Group. Polypharmacy Guidance Realistic Prescribing; 2018.

Blanco E, Valdellos J. Polyphamacy: Something more so just numbers. Med Clin. (Barc) .2019.153 (4): 154-156.

Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc . [Internet] 2017 [Cited July 05 2021];57(6):729-738.e10. doi: 10.1016/j.japh.2017.06.002.

Rodríguez MC, Oliveira C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Rev Lat Emfermagem. 2016; 24, 1-17.

Linares-Cánovas L, Lemus-Fajardo N, Linares-Cánovas L, Lazo-Herrera L, Díaz-Pita G. Caracterización de pacientes adultos mayores con tratamiento farmacológico antihipertensivo atendidos en el hospital “Dr. León Cuervo Rubio”. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta [Internet]. 2017 [citado 26 Jul 2022]; 42 (6) Disponible en: http://www.revzoilomarinello.sld.cu/index.php/zmv/article/view/1184

Martin-Pérez M, López de Andrés A, Hernández-Barrera V, et al. Prevalencia de polifarmacia en la población mayor de 65 años en España: análisis de las Encuestas Nacionales de Salud 2006 y 2011. Rev Esp Geriatr Gerontol [Internet] 2017[Cited July 05 2021] ;52(1):2-8. doi:10.1016/j.regg.2016.07.006

Ramírez-Duque N, Rivas-Cobas C, Bernabeu-Wittel M, et al. Perfil de prescripción farmacológica en pacientes con enfermedades crónicas no neoplásicas en fase avanzada. Rev Esp Gastrontol. 2014 [Internet]; 49 (6) [Cited July 05 2021]. Disponible en: doi:10.1016/j.regg.2014.01.006

World Health Organization. Noncommunicable Diseases. [Internet] 2019[Cited July 05 2021] Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/noncommunicable-diseases

Barba EJR. Mexico and the challenge of chronic non-communicable diseases. The laboratory also plays an important role. Rev Mex Patol Clin Med Lab. 2018;65(1):4-17.

Pizarro D. Polypharmacy and prescription in older adults. Medical Journal of Costa Rica and Central America LXXIII (919) 389-394,2016.

Population pyramid. Population Pyramids of the World from 1950 to 2100. [Internet] Mexico; 2019 [Cited July 05 2021] Disponible en: https://www.populationpyramid.net/mexico/2019/.

Wallace J, Paauw DS. Appropriate prescribing and important drug interactions in older adults. Med Clin North Am. [Internet] 2015 [Cited July 05 2021];99(2):295-310. Disponible en: doi:10.1016/j.mcna.2014.11.005

Welker KL, Mycyk MB. Pharmacology in the Geriatric Patient. Emerg Med Clin North Am. [Internet] 2016[Cited July 05 2021];34(3):469-481. Disponible en: doi:10.1016/j.emc.2016.04.003

Gómez Aguirre N, Caudevilla Martínez A, Bellostas Muñoz L, Crespo Avellana L, Velilla Marco J, Díez Manglano J. Pluripatología, polifarmacia, complejidad terapéutica y uso adecuado de la medicación. Rev Clin Esp. [Internet] 2017 [Cited July 05 2021]; 217 (5): 209-295. Disponible en: doi: 10.1016/j.rce.2016.12.013

Publicado

2022-10-30

Cómo citar

Sánchez-Hernádez, V., Morales-Pérez, M., & Osorio-Espinoza, A. (2022). Polypharmacy in patients with chronic-degenerative diseases in a remote community, Puebla- México. Revista Médica De Risaralda, 28(2). https://doi.org/10.22517/25395203.25046

Número

Sección

Artículo original